May 20 | 2025 2cureX Conducts First Direct-to-Patient IndiTreat® Test Under “Operation Twin Code” Strategy Read more
May 15 | 2025 2cureX AB (2CUREX) Launches “Operation Twin Code” with New Investors, Leadership Transition, and Global Roadmap Read more
January 20 | 2025 2CUREX APPOINTS MANGOLD FONDKOMMISSION AB TO ACT AS A LIQUIDITY PROVIDER FOR THE COMPANY’S SHARE Read more
January 10 | 2025 Correction: 2CUREX APPOINTS MANGOLD FONDKOMMISSION AB TO ACT AS A LIQUIDITY PROVIDER FOR THE COMPANY’S SHARE Read more
January 10 | 2025 2CUREX APPOINTS MANGOLD CORPORATE FINANCE TO ACT AS A LIQUIDITY PROVIDER FOR THE COMPANY’S SHARE Read more
December 16 | 2024 2cureX AB Announces the Appointment of Dan Honeywell as CEO, Ushering in a New Era of commercial expansion of breakthrough precision oncology products Read more